In the first Parallax episode of 2021, Ankur welcomed back Sukh Nijjer from Imperial College London to review the most impactful events and advances in cardiology from 2020.
In the first part of the episode, Ankur and Sukh focus on the mechanism of the coronavirus and its effects on the heart including clotting abnormality and troponin elevation. They discuss their clinical experiences and observations within the UK and US settings in light of the latest data. Sukh offers practical tips on how to approach patient management during this pandemic.
Following this, Ankur and Sukh analyse the controversial STRENGHT study in light of the results from REDUCE-IT. They discuss the different attitudes toward early cryoablation therapy in the context of STOP AF and EARLY-AF studies. Sukh reviews the findings of the RHAPSODY Phase 3 trial and the revolution of SGLT2 inhibitors in the treatment of heart failure.
Which COVID19 patients require risk stratification with a stress test? What are the take-home messages for physicians taking care of patients diagnosed with COVID19? What were the key trials of 2020? What can we learn from the negative results of the STRENGHT study? How have studies like STOP-AF influenced clinical practice?
Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @SukhNijjer, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Sponsored by Edwards.
Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
In this week’s episode Ankur’s guest is Dr Mandeep R Mehra, Medical Director of Brigham Heart and Vascular Center and Professor of Medicine at Harvard Medical School.
Which COVID19 patients require risk stratification with a stress test? What are the take-home messages for physicians taking care of patients diagnosed with COVID19? What were the key trials of 2020? What can we learn from the negative results of the STRENGHT study? How have studies like STOP-AF influenced clinical practice?
What makes Dr Martin B Leon tick? What is his message to cardiologists and/or researchers at the beginning of their careers? How did the pandemic and his work as a clinician in New York change his perspective?